uniQure N.V. Contracts & Agreements

Asset Purchase Agreement, by and among uniQure Inc., uniQure biopharma B.V., Genezen Holdings Inc. and Genezen MA, Inc., dated as of June 29, 2024 (Filed With SEC on August 1, 2024)

Consent and Amendment No. 2 to Loan and Security Agreement, dated June 28, 2024, by and among uniQure biopharma, B.V., uniQure, Inc., uniQure IP B.V., the Company and Hercules... (Filed With SEC on August 1, 2024)

Landlord Consent to Assignment and Assumption of Lease and Third Amendment to Lease, dated June 28, 2024, by and among Hartwell Innovation Campus, LLC, uniQure, Inc. and Genezen... (Filed With SEC on August 1, 2024)

Assignment and Assumption of Lease, dated July 22, 2024, by and between uniQure, Inc. and Genezen MA, Inc (Filed With SEC on August 1, 2024)

Termination Agreement, dated July 22, 2024, by and between uniQure biopharma B.V. and Pierre Caloz (Filed With SEC on August 1, 2024)

Amended and Restated 2014 Share Incentive Plan of uniQure N.V. (conformed to include the Second Amendment to the Amended and Restated 2014 Share Incentive Plan attached as... (Filed With SEC on June 20, 2024)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 28, 2024)

Employment Agreement dated July 30, 2021 between Corlieve Therapeutics AG and Richard Porter (Filed With SEC on February 28, 2024)

First Amended Employment Agreement dated April 1, 2022 between Corlieve Therapeutics AG and Richard Porter (Filed With SEC on February 28, 2024)

Letter Agreement dated October 5, 2023, by and between Richard Porter and Corlieve Therapeutics AG (Filed With SEC on February 28, 2024)

Employment Agreement dated June 13, 2023 between uniQure, Inc. and Jeannette Potts (Filed With SEC on February 28, 2024)

Amended and Restated 2014 Share Incentive Plan of uniQure N.V. (conformed to include the First Amendment to the Amended and Restated 2014 Share Incentive Plan attached as Appendix... (Filed With SEC on November 17, 2023)

Termination and Consulting Agreement, effective October 4, 2023, by and between uniQure, Inc. and Ricardo Dolmetsch, Ph.D (Filed With SEC on November 7, 2023)

Amendment No. 1 to Third Amended and Restated Loan and Security Agreement, dated as of May 12, 2023, by and among uniQure biopharma, B.V., uniQure, Inc., uniQure IP B.V., uniQure... (Filed With SEC on August 1, 2023)

Royalty Purchase Agreement, dated May 12, 2023, by and between uniQure biopharma B.V. and HemB SPV, L.P (Filed With SEC on August 1, 2023)

Consulting Agreement, effective March 31, 2023, by and between uniQure, Inc., and Alex Kuta (Filed With SEC on May 9, 2023)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2023)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 25, 2022)

Form of Share Option Agreement, effective December 8, 2021, under the 2014 Share Incentive Plan (Filed With SEC on February 25, 2022)

Form of Restricted Stock Unit Award, effective December 8, 2021, under the 2014 Share Incentive Plan (Filed With SEC on February 25, 2022)

Form of Performance Stock Unit Award, effective December 8, 2021 under the 2014 Share Incentive Plan (Filed With SEC on February 25, 2022)

Third Amended and Restated Loan and Security Agreement as of December 15, 2021, by and among uniQure biopharma B.V., uniQure Inc., uniQure IP B.V., the Company and Hercules... (Filed With SEC on February 25, 2022)

Lease Agreement relating to 20 Maguire Road, Lexington, Massachusetts, dated as of December 22, 2021, by and between uniQure Inc. and G&I IX/GP4 20 Maguire LLC (Filed With SEC on February 25, 2022)

Lease Agreement relating to 91 Hartwell Avenue, Lexington, Massachusetts, dated as of February 1, 2022, by and between uniQure Inc. and NRL 91 Hartwell LLC (Filed With SEC on February 25, 2022)

Consent and Amendment No. 3 to Second Amended and Restated Loan and Security Agreement, dated July 30, 2021, by and among the Registrant, Hercules Capital Inc., and the other... (Filed With SEC on October 25, 2021)

Sale and Purchase Agreement, executed June 21, 2021, by and between uniQure N.V. and Corlieve Therapeutics SAS (Filed With SEC on July 26, 2021)

t2014 Share Incentive Plan, Amended and Restated, effective as of June 16, 2021 (Filed With SEC on July 26, 2021)

t Employment Agreement, effective May 17, 2021, by and between uniQure biopharma B.V. and Pierre Caloz (Filed With SEC on July 26, 2021)

t Equity Side Letter, effective May 17, 2021, by and between uniQure N.V. and Pierre Caloz (Filed With SEC on July 26, 2021)

tAmended and Restated Employment Agreement, effective June 15, 2021, by and between uniQure biopharma B.V. and Christian Klemt (Filed With SEC on July 26, 2021)

Cooperation Agreement, dated as of April 16, 2021, by and among uniQure N.V., ForUniqure B.V., Forbion 1 Management B.V., Forbion International Management B.V., and Forbion... (Filed With SEC on May 10, 2021)

Sales Agreement dated March 1, 2021 by and between uniQure N.V. and SVB Leerink LLC (Filed With SEC on March 2, 2021)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 1, 2021)

Amendment to Collaboration and License Agreement by and between uniQure Biopharma B.V. and Bristol-Myers Squibb Company dated December 1, 2020 (Filed With SEC on March 1, 2021)

Amendment No. 2 to Second Amended and Restated Loan and Security Agreement as of January 29, 2021 by and among uniQure Biopharma B.V., uniQure, Inc., uniQure IP B.V., the Company... (Filed With SEC on March 1, 2021)

Separation agreement, executed August 25, 2020, by and between uniQure biopharma B.V. and Sander van Deventer (Filed With SEC on October 27, 2020)

Separation agreement, executed August 25, 2020, by and between uniQure Inc. and Robert Gut (Filed With SEC on October 27, 2020)

103* Employment agreement, executed September 14, 2020, by and between uniQure Inc. and Ricardo Dolmetsch (Filed With SEC on October 27, 2020)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2020)

Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure biopharma B.V. and Christian Klemt (Filed With SEC on March 2, 2020)

Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure Inc. and Dr. Robert Gut (Filed With SEC on March 2, 2020)

Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure Inc. and Maria Cantor (Filed With SEC on March 2, 2020)

Amended and Restated Employment Agreement, executed March 1, 2020 by and between uniQure Inc. and Jonathan Garen (Filed With SEC on March 2, 2020)

Sales Agreement dated March 2, 2020 by and between uniQure N.V. and SVB Leerink LLC (Filed With SEC on March 2, 2020)

Amended and Restated Collaboration Agreement by and between 4D Molecular Therapeutics, Inc and uniQure biopharma B.V., dated August 6, 2019 (Filed With SEC on October 28, 2019)

Collaboration and License Agreement by and between 4D Molecular Therapeutics, Inc and uniQure biopharma B.V., dated August 6, 2019 (Filed With SEC on October 28, 2019)

Amended and Restated Employment Agreement, executed September 17, 2019, by and between the Company and Dr. Kuta (Filed With SEC on September 20, 2019)

Employment Agreement, executed September 17, 2019, by and between the Company and Dr. Sander van Deventer (Filed With SEC on September 20, 2019)

Separation Agreement, executed September 16, 2019, by and between the Company and Dr. Scott McMillan (Filed With SEC on September 20, 2019)

Underwriting Agreement between the Company, Goldman Sachs & Co. LLC and SVB Leerink LLC, as representatives for the underwriters named therein, dated as of September 5, 2019 (Filed With SEC on September 6, 2019)

Second Amendment Lease relating to 113 Hartwell Avenue, Lexington Massachusetts, dated as of June 17, 2019, by and between the Company and King 113 Hartwell LLC (Filed With SEC on July 29, 2019)

Form of Share Option Agreement, effective June 18, 2019, under the 2014 Share Incentive Plan (Filed With SEC on July 29, 2019)

Employment Agreement dated August 20, 2018 by and between uniQure, Inc. and Dr. Robert Gut (Filed With SEC on February 28, 2019)

Amendment No. 1 to Second Amended and Restated Loan and Security Agreement dated December 6, 2018 (Filed With SEC on December 10, 2018)

113 Hartwell Avenue Lexington, Massachusetts (the Building) FIRST AMENDMENT As of November 9, 2018 (Execution Date) (Filed With SEC on November 15, 2018)

Underwriting Agreement between the Company and Leerink Partners LLC, as representative for the underwriters named therein, dated as of May 2, 2018 (Filed With SEC on May 3, 2018)

Form of Restricted Stock Unit Award under the 2014 Share Incentive (Filed With SEC on March 14, 2018)

Form of Performance Stock Unit Award under the 2014 Share Incentive Plan (Filed With SEC on March 14, 2018)

Letter agreement dated October 26, 2017 between uniQure N.V. and Matthew Kapusta, amending Mr. Kapustas employment agreement dated December 9, 2014, as amended (Filed With SEC on November 1, 2017)

Underwriting Agreement between the Company and Leerink Partners LLC, as representative for the underwriters named therein, dated as of October 24, 2017 (Filed With SEC on October 26, 2017)

Assignment and License Agreement dated April 17, 2017 between Professor Paolo Simioni and uniQure biopharma B.V (Filed With SEC on October 19, 2017)

Sales Agreement dated September 15, 2017 by and between uniQure N.V. and Leerink Partners LLC (Filed With SEC on September 18, 2017)

uniQure biopharma B.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands (Filed With SEC on August 8, 2017)

employment AGREEMENT PURSUANT TO SECTION 7:610 (et seq.) of the Dutch Civil Code (DCC) (Filed With SEC on August 8, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 8, 2017)

employment AGREEMENT PURSUANT TO SECTION 7:610 (et seq.) of the Dutch Civil Code (DCC) (Filed With SEC on August 8, 2017)

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT - NONEXCLUSIVE COVER PAGE (Filed With SEC on May 9, 2017)

PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT - EXCLUSIVE and NON-EXCLUSIVE COVER PAGE (Filed With SEC on May 9, 2017)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on May 9, 2017)

CO-DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on May 9, 2017)

uniQure N.V. 2014 Share Incentive Plan (Amended and Restated effective as of June 15, 2016) (Filed With SEC on March 15, 2017)

uniQure N.V. Share Option Agreement (Filed With SEC on March 15, 2017)

uniQure N.V. Share Option Agreement Granted Under 2014 Share Incentive Plan, Amended and Restated effective as of June 15, 2016 (Filed With SEC on March 15, 2017)

uniQure N.V. Restricted Share Unit Agreement Granted Under 2014 Share Incentive Plan, As Amended and Restated NOTICE OF GRANT (Filed With SEC on March 15, 2017)

uniQure N.V. Performance Share Unit Agreement Granted Under 2014 Share Incentive Plan, Amended and Restated effective as of June 15, 2016 NOTICE OF GRANT (Filed With SEC on March 15, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2017)

CONSULTANCY SERVICES AGREEMENT (Filed With SEC on March 15, 2017)

UNIQURE SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (Filed With SEC on March 15, 2017)

(signature Lessee) (Filed With SEC on March 15, 2017)

Category

Industry

Companies

Contracts

uniQure N.V. Contracts & Agreements